Compare AstraZeneca plc (AZN) vs Wells Fargo & Co (WFC) Price & Performance

AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.

The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.

Wells Fargo (WFC) trades at $87.70, up 0.67% with a bullish technical outlook. The stock shows strong fundamentals with Q2 2026 EPS beating estimates at $2.00 versus $1.73 expected, driven by net interest income and fee growth. Revenue trends upward from $83.7B in 2025 to projected $85.0B in 2026, while net income margin remains robust at 25.5%. Recent news highlights the bank's $1B+ technology investment in AI tools for wealth management and a healthy investment banking pipeline.

The outlook is positive with a consensus price target of $99.10 offering 13% upside. Key opportunities include continued earnings momentum and efficiency gains from tech investments. Risks involve expense pressures, macroeconomic sensitivity, and competitive banking sector dynamics. Analyst sentiment is mixed with 45% buy ratings but near-term execution on guidance will be critical for sustained outperformance.